Massachusetts General Hospital
Locations
Transplant Summary
Overview
MGH is a FACT accredited program. The Hematopoietic Cell Transplant and Cellular Therapy (HCTCT) program offers a comprehensive range of transplant services including myeloablative and reduced intensity matched related and unrelated donor transplants, umbilical cord blood transplants and haploidentical donor transplants as well as recent advances in gene modified autologous and allogeneic cellular therapy products such as chimeric antigen receptor T-cells (CAR-T). Our program has state of the art facilities for both inpatient and outpatient care that includes a 32 bed inpatient unit.This center has been performing allogeneic transplants since 1993 and has been an NMDP transplant center since October 2007.
Attending physicians
Adult - Yi Bin Chen, Zachariah DeFilipp, Areej El-Jawahri, Matthew Frigault, Mark Leick, Steven McAfee, Richard Newcomb, Paul O'Donnell, Thomas SpitzerTransplants performed
Marrow/PBSC, single cord, and double cordCord blood transplants
Adult onlyOther programs and services
Please visit: https://www.massgeneral.org/cancer-center/treatments-and-services/bone-marrow-transplantPatient survival information for this center
This center's actual 1-year survival results are similar to the expected rate for this center*.The survival information we have for this center includes ONLY:- Patients who had their FIRST ALLOGENEIC transplant (cells from a related or unrelated donor/cord blood) during 2020, 2021, 2022 and
- Who had their transplant at a U.S. transplant center, and
- Who had follow-up information provided by the transplant center for analysis
For this center, we have survival information for 274 patients.The actual 1-year survival of these patients is 81.3%.Compared to similar patients transplanted at all centers in the U.S., we expect that the 1-year survival for patients at this center to be in a range between 71.8% and 81.4%.For help with understanding these statistics, please see Understanding Transplant Outcomes.For overall survival for all patients transplanted with a specific disease, please see U.S. Patient Survival report (Opens in a new tab) at bloodcell.transplant.hrsa.gov.* The expected survival rate for a transplant center can be below, similar to, or above the range listed. This is based on comparing patient survival at all centers that treated patients with similar diseases.
The survival rate cannot tell how you will do with your transplant. Talk to your doctor to understand your prognosis or the likely course of your disease.
Total adult transplants
318
Transplants reported by the centers (from January 1, 2022 to December 31, 2023)
Marrow PBSC Cord blood Total AllogeneicRelated donorMarrow10PBSC63Cord blood0Total73Unrelated donorMarrow11PBSC138Cord blood0Total149Total allogeneicMarrow21PBSC201Cord blood0Total222AutologousMarrowBoth marrow & PBSC 96PBSC—Cord blood—Total96Total combinedMarrowBoth marrow & PBSC 318PBSC—Cord blood0Total318Total pediatric transplants
5
Transplants reported by the centers (from January 1, 2022 to December 31, 2023)
Marrow PBSC Cord blood Total AllogeneicRelated donorMarrow1PBSC0Cord blood0Total1Unrelated donorMarrow0PBSC1Cord blood0Total1Total allogeneicMarrow1PBSC1Cord blood0Total2AutologousMarrowBoth marrow & PBSC 3PBSC—Cord blood—Total3Total combinedMarrowBoth marrow & PBSC 5PBSC—Cord blood0Total5All Diseases
Number of transplants by age reported from January 1, 2022 to December 31st, 2023(includes marrow, PBSC and cord blood)
0-18 19-44 45-64 65+ Total Related 0-18119-441745-643065+23Total71Unrelated 0-18119-441645-646165+70Total148Autologous 0-18419-441345-644965+33Total99Total 0-18619-444645-6414065+126Total318Treatments may be similar for diseases within a group. It might be helpful to look at centers that have done transplants for a specific disease and centers that have done transplants for any corresponding broad disease categories.
Centers are not required to report autologous transplants so the numbers might be incomplete.
More information about transplants can be found:
- U.S. Transplant Data by Center (Opens in a new tab) report at blood cell.transplant.hrsa.gov
- List of diseases
Transplant center resources
NMDP patient navigators
Patient navigators can answer your questions about choosing a transplant center and provide support and education to help you throughout your transplant journey.
- Inside the United States: 1 (888) 999-6743
- Outside the United States: 1 (763) 406-3410. (Long distance or international charges may apply.)
Email: patientinfo@nmdp.org
More resources
- Choosing a transplant center
- Preparing for transplant
- Learn about transplant outcomes and treatment decisions (Opens in a new tab)
- Support and resources (including non-English materials)
- U.S. Transplant Data by Center (Opens in a new tab) at blood cell.transplant.hrsa.gov
Massachusetts General Hospital BMT Survivorship
55 Fruit Street, Yawkey 9E Boston, MA 2114 Phone:617-726-5765 For more information about this program: https://www.massgeneral.org/cancer/Survivorship/BMT.aspx (Opens in a new tab)Overview
The goal of this program is to improve the experience and outcomes of bone marrow transplant (BMT) survivors and their families by: Providing high-quality clinical survivorship care Conducting innovative research to enhance the delivery, experience, and quality of life and care for BMT survivors, their families, and caregivers. Program Co-Director - Julie Vanderklish, NP Associate Director - Richard Newcomb, MD Social Work Lead - Jennifer D'Alotto, LICSW
Staff
Program Director:Areej El-Jawahri, MDProgram Coordinator:Julie Vanderklish, NPMedical Specialties in Program
Cardiology, complementary and alternative medicine, dermatology, endocrinology, gastroenterology, general surgery, gynecology, hematology, hepatology, infectious disease, nephrology, neurology, oncology, ophthalmology/optometry, orthopedics, palliative care, psychiatry/psychology, pulmonology, rheumatology, urology.Medical Services Offered
Chronic GVHD management, financial counseling, nutrition/dietetics, occupational therapy, pain management, physical therapy and rehabilitation, sexual health, social services, vaccinations.Telemedicine services are available.Patient Eligibility
Adults- Allogeneic transplant recipients
- Adults: 10 months after transplant.
- Adults (over age 18 years)
- Will provide care to adult patients who underwent transplant as a child
- Does accept patients who were transplanted at another hospital